TY - JOUR
T1 - The dismal outcome in patients with acute leukaemia who relapse after an autograft is improved if a second autograft or a matched allograft is performed
AU - Ringdén, O.
AU - Labopin, M.
AU - Gorin, N. C.
AU - Meloni, G.
AU - Biaise, D.
AU - Reiffers, J.
AU - Carlson, K.
AU - Fouillard, L.
AU - Frassoni, F.
PY - 2000
Y1 - 2000
N2 - All patients receiving autografts for acute leukaemia in remission between 1 January 1981 and 31 December 1996 and reported to the European Group for Blood and Marrow Transplantation and had a relapse, were included. The patients underwent an allograft (n = 90, group A), were treated with chemotherapy (n = 2584, group B) or received a second autograft (n = 74, group C). The 2-year survival after relapse was 32 ± 5%, 11 ± 1% and 42 ± 6% in groups A, B and C, respectively. In group A, those with an HLA-A, -B and -DR compatible related or unrelated donor had a 2-year survival of 37 ± 7% compared to 13 ± 8% for those receiving a graft from an HLA mismatched donor (n = 20). The following factors were associated with better survival in multivariate analyses: an interval from first autograft to relapse > 5 months (P <0.00001), a first autograft performed later than 1991 (P <0.00001), patient age below 26 years (median, P <0.002), group B vs HLA mismatches from group A (P = 0.002), group C vs group B (P <0.005), patients who were not treated with total body irradiation at first autograft (P <0.02) and patients in first remission at first autograft (P = 0.02). To conclude, the poor outcome in these patients was improved if a second autograft was feasible (P <0.005), or if an HLA-matched allograft was performed (NS).
AB - All patients receiving autografts for acute leukaemia in remission between 1 January 1981 and 31 December 1996 and reported to the European Group for Blood and Marrow Transplantation and had a relapse, were included. The patients underwent an allograft (n = 90, group A), were treated with chemotherapy (n = 2584, group B) or received a second autograft (n = 74, group C). The 2-year survival after relapse was 32 ± 5%, 11 ± 1% and 42 ± 6% in groups A, B and C, respectively. In group A, those with an HLA-A, -B and -DR compatible related or unrelated donor had a 2-year survival of 37 ± 7% compared to 13 ± 8% for those receiving a graft from an HLA mismatched donor (n = 20). The following factors were associated with better survival in multivariate analyses: an interval from first autograft to relapse > 5 months (P <0.00001), a first autograft performed later than 1991 (P <0.00001), patient age below 26 years (median, P <0.002), group B vs HLA mismatches from group A (P = 0.002), group C vs group B (P <0.005), patients who were not treated with total body irradiation at first autograft (P <0.02) and patients in first remission at first autograft (P = 0.02). To conclude, the poor outcome in these patients was improved if a second autograft was feasible (P <0.005), or if an HLA-matched allograft was performed (NS).
KW - Acute leukaemia
KW - Allogeneic bone marrow transplantation
KW - Autologous stem cell transplantation
KW - Relapse
UR - http://www.scopus.com/inward/record.url?scp=0034024209&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034024209&partnerID=8YFLogxK
M3 - Article
C2 - 10828865
AN - SCOPUS:0034024209
VL - 25
SP - 1053
EP - 1058
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 10
ER -